Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)

Chung Hwan Chen; Seung Jae Lim; Jong Keon Oh; Tsan Wen Huang; Yuhong H. Zeng; Meng Ting Wu; Huilin L. Yang; Jason Pui Yin Cheung; Ji Wan Kim; Jeong Hee Han; Li Huo; Tsung Jung Lin; Gang Zhou; Wen Shuo Wu

doi:10.2147/CIA.S228158

Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)

Chung Hwan Chen, Seung Jae Lim, Jong Keon Oh, Tsan Wen Huang, Yuhong H. Zeng, Meng Ting Wu, Huilin L. Yang, Jason Pui Yin Cheung, Ji Wan Kim, Jeong Hee Han, Li Huo, Tsung Jung Lin, Gang Zhou, Wen Shuo Wu

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Purpose: The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia. Patients and Methods: The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan. Results: The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were −3.11 (1.54), −2.58 (1.11), and −2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5LVisual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2). Conclusion: Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.

Original language	English
Pages (from-to)	111-121
Number of pages	11
Journal	Clinical Interventions in Aging
Volume	15
DOIs	https://doi.org/10.2147/CIA.S228158
Publication status	Published - 2020

Bibliographical note

Funding Information:
The authors thank Fernando Marin (MD, PhD), global study physician, Thomas Moll (PhD, MBA), clinical trial manager, Alan Brnabic (MSc), study statistician, and Sheetal Pradhan (MD), medical writer, for their contributions to this manuscript. All are employees of Eli Lilly and Company. The authors also thank Ms. Sin Ting Lau for her help in study support. Eli Lilly and Company sponsored the ALAFOS study. Unique study identifier for the ALAFOS study: B3D-MC-B026.

Publisher Copyright:
© 2020 Chen et al.

Keywords

East Asia
Fractures
Observational study
Postmenopausal osteoporosis
Teriparatide

ASJC Scopus subject areas

Geriatrics and Gerontology

Access to Document

10.2147/CIA.S228158

Cite this

Chen, C. H., Lim, S. J., Oh, J. K., Huang, T. W., Zeng, Y. H., Wu, M. T., Yang, H. L., Cheung, J. P. Y., Kim, J. W., Han, J. H., Huo, L., Lin, T. J., Zhou, G., & Wu, W. S. (2020). Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS). Clinical Interventions in Aging, 15, 111-121. https://doi.org/10.2147/CIA.S228158

Chen, CH, Lim, SJ, Oh, JK, Huang, TW, Zeng, YH, Wu, MT, Yang, HL, Cheung, JPY, Kim, JW, Han, JH, Huo, L, Lin, TJ, Zhou, G & Wu, WS 2020, 'Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)', Clinical Interventions in Aging, vol. 15, pp. 111-121. https://doi.org/10.2147/CIA.S228158

@article{2caac482e0ad49cf980a3693cebd4a81,

title = "Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)",

abstract = "Purpose: The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia. Patients and Methods: The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan. Results: The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were −3.11 (1.54), −2.58 (1.11), and −2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5LVisual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2). Conclusion: Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.",

keywords = "East Asia, Fractures, Observational study, Postmenopausal osteoporosis, Teriparatide",

author = "Chen, {Chung Hwan} and Lim, {Seung Jae} and Oh, {Jong Keon} and Huang, {Tsan Wen} and Zeng, {Yuhong H.} and Wu, {Meng Ting} and Yang, {Huilin L.} and Cheung, {Jason Pui Yin} and Kim, {Ji Wan} and Han, {Jeong Hee} and Li Huo and Lin, {Tsung Jung} and Gang Zhou and Wu, {Wen Shuo}",

note = "Funding Information: The authors thank Fernando Marin (MD, PhD), global study physician, Thomas Moll (PhD, MBA), clinical trial manager, Alan Brnabic (MSc), study statistician, and Sheetal Pradhan (MD), medical writer, for their contributions to this manuscript. All are employees of Eli Lilly and Company. The authors also thank Ms. Sin Ting Lau for her help in study support. Eli Lilly and Company sponsored the ALAFOS study. Unique study identifier for the ALAFOS study: B3D-MC-B026. Publisher Copyright: {\textcopyright} 2020 Chen et al.",

year = "2020",

doi = "10.2147/CIA.S228158",

language = "English",

volume = "15",

pages = "111--121",

journal = "Clinical Interventions in Aging",

issn = "1176-9092",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting

T2 - A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)

AU - Chen, Chung Hwan

AU - Lim, Seung Jae

AU - Oh, Jong Keon

AU - Huang, Tsan Wen

AU - Zeng, Yuhong H.

AU - Wu, Meng Ting

AU - Yang, Huilin L.

AU - Cheung, Jason Pui Yin

AU - Kim, Ji Wan

AU - Han, Jeong Hee

AU - Huo, Li

AU - Lin, Tsung Jung

AU - Zhou, Gang

AU - Wu, Wen Shuo

N1 - Funding Information: The authors thank Fernando Marin (MD, PhD), global study physician, Thomas Moll (PhD, MBA), clinical trial manager, Alan Brnabic (MSc), study statistician, and Sheetal Pradhan (MD), medical writer, for their contributions to this manuscript. All are employees of Eli Lilly and Company. The authors also thank Ms. Sin Ting Lau for her help in study support. Eli Lilly and Company sponsored the ALAFOS study. Unique study identifier for the ALAFOS study: B3D-MC-B026. Publisher Copyright: © 2020 Chen et al.

PY - 2020

Y1 - 2020

N2 - Purpose: The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia. Patients and Methods: The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan. Results: The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were −3.11 (1.54), −2.58 (1.11), and −2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5LVisual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2). Conclusion: Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.

AB - Purpose: The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia. Patients and Methods: The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan. Results: The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were −3.11 (1.54), −2.58 (1.11), and −2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5LVisual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2). Conclusion: Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.

KW - East Asia

KW - Fractures

KW - Observational study

KW - Postmenopausal osteoporosis

KW - Teriparatide

UR - http://www.scopus.com/inward/record.url?scp=85079447786&partnerID=8YFLogxK

U2 - 10.2147/CIA.S228158

DO - 10.2147/CIA.S228158

M3 - Article

C2 - 32099341

AN - SCOPUS:85079447786

SN - 1176-9092

VL - 15

SP - 111

EP - 121

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

ER -

Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this